{"id":40567,"date":"2021-05-03T07:19:36","date_gmt":"2021-05-03T07:19:36","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=40567"},"modified":"2022-01-17T17:57:18","modified_gmt":"2022-01-17T17:57:18","slug":"no-impact-from-anakinra-in-mild-moderate-covid-19-pneumonia","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/40567","title":{"rendered":"No impact from anakinra in mild\/moderate COVID-19 pneumonia"},"content":{"rendered":"<div>\n<p class=\"HTBsubhead2articletitle\"><strong><span lang=\"EN-US\"><img loading=\"lazy\" decoding=\"async\" class=\" alignright\" src=\"https:\/\/i-base.info\/wp-content\/uploads\/2020\/03\/COVID-19-graphic.png\" width=\"231\" height=\"142\" \/><\/span>Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><strong><span lang=\"EN-US\">Although early studies suggested the rheumatoid arthritis drug anakinra might have a positive impact on reducing inflammation in COVID-19, this was not seen in participants with mild to moderate pneumonia in the randomised CORIUMO study.<\/span><\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">The study\u00a0<\/span>screened 153 patients and enrolled of 116 patients, roughly half in the active and placebo groups. However, based on lack of difference in symptoms at day 4 or day 14, and a similar lack of difference in mortality at day 90 (27% in each group), the study was closed early based on a recommendation from the independent data and safety monitoring board (DSMB).<\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">Further studies are be needed to see whether there is an effect for other COVID-19 indications.<\/p>\n<\/div>\n<div>\n<p class=\"HTBreference-noindent\"><span lang=\"EN-US\">Reference<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBreference-noindent\">The CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respiratory Medicine 9(3):295-304 (March 2021).<br \/>\n<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213260020305567\">https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213260020305567<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base Although early studies suggested the rheumatoid arthritis drug anakinra might have a positive impact on reducing inflammation in COVID-19, this was not seen in participants with mild to moderate pneumonia in the randomised CORIUMO study. The &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[283,278],"tags":[],"class_list":["post-40567","post","type-post","status-publish","format-standard","hentry","category-covid-19-investigational-drugs","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=40567"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40567\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=40567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=40567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=40567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}